-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4586 PHF6 Mutation in Chronic Myelomonocytic Leukemia Is Associated with Chronic Thrombocytopenia and Predicts Superior Overall and Leukemia-Free Survival

Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Research, Epidemiology, Clinical Research, CMML, Chronic Myeloid Malignancies, Diseases, Real-world evidence, Biological Processes, Myeloid Malignancies, Technology and Procedures
Monday, December 9, 2024, 6:00 PM-8:00 PM

Saubia Fathima, MD1, Ali Alsugair, MBBS2, Anuya A. Natu1*, Clifford M. Csizmar, MD, PhD3, Mark Gurney, MB, BCh, BAO4*, Terra L. Lasho, PhD4, Christy Finke, BS4*, Abhishek A. Mangaonkar, MBBS1, Kaaren K. Reichard, MD5, Rong He, MD6, Animesh D. Pardanani, MBBS, PhD3, Naseema Gangat, MBBS4, Mrinal M. Patnaik, MD, MBBS1 and Ayalew Tefferi, MD4

1Mayo Clinic, Rochester, MN
2Department of Hematology, Mayo Clinic, Rochester, MN
3Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
4Division of Hematology, Mayo Clinic, Rochester, MN
5Department of Pathology, Mayo Clinic, Rochester, MN
6Division of Hematopathology, Mayo Clinic, Rochester, MN

Background:

The majority of patients with chronic myelomonocytic leukemia (CMML) harbor somatic mutations with the most frequent being TET2 (56%), SRSF2 (42%), and ASXL1 (41%) (Leukemia 2020;34:1407). The prognostic relevance of mutations in CMML has been studied extensively with consistent observations suggesting favorable survival impact from TET2 and unfavorable from DNMT3A, ASXL1, NRAS, and SETBP1 mutations. Among the latter, DNMT3A mutation stands out as being the strongest predictor of inferior overall (OS) and leukemia-free (LFS) survival (AJH 2017;92:56). The current study was inspired by observations from exploratory analyses of a large Mayo Clinic CMML cohort.

Methods:

The current retrospective study was conducted under an institutional review board approved minimum risk protocol that allowed retrospective collection and analysis of data from patient records (Mayo Clinic, Rochester, MN; Scottsdale, AZ; and Jacksonville, FL). Mutations were screened by multi-gene next-generation sequencing (NGS). Diagnostic criteria were according to the International Consensus Classification (Blood 2022; 140:1200). Conventional statistical methods were employed for comparisons of groups and survival analysis (JMP Pro 17.0.0 software SAS Institute, Cary, NC, USA).

Results:

Exploratory analysis of a well-characterized cohort of 398 Mayo Clinic patients with CMML suggested an unusually long median survival of 96 months for 7 patients harboring PHF6 mutation vs. 27 months for those without the mutation. A subsequent institutional database search focusing on PHF6-mutated CMML identified 20 more cases, expanding the total number of study patients to 418, including 27 PHF6-mutated cases. PHF6 mutations clustered with (co-mutation frequency) TET2 (93%) and less likely to be co-mutated with TP53 (0%), PTPTN11 (0%) and SF3B1 (0%) mutations. PHF6-mutated patients often presented with thrombocytopenia (platelet count <100 x 10(9)/L; 85% vs. 51% in PHF6 wild-type cases; p<0.01). Median time from initial presentation with thrombocytopenia to CMML diagnosis was 4 years (0-14 years).

In order to isolate the prognostic impact of PHF6 mutation without associated DNMT3A mutation and independent of TET2 mutation, we considered 4 mutational categories: i) DNMT3A-mutated (N=19; 2 co-expressed PHF6 and 7 TET2 mutations), ii) PHF6-mutated with wild-type DNMT3A (N=25; 23 co-expressed TET2 mutation), iii) TET2-mutated without DNMT3A or PHF6 co-expression (N=169), and iv) wild-type for DNMT3A, TET2, and PHF6 (N=205). Compared to the other groups, PHF6-mutated patients with wild-type DNMT3A were less likely to display leukocytosis (p<0.01) or red cell transfusion need at presentation (p<0.01).

At a median follow-up of 18 months, 302 deaths, 78 leukemic transformations, and 44 allogenic stem cell transplants were documented. Univariate analysis for OS disclosed superiority in favor of PHF6-mutated patients with wild-type DNMT3A (median OS 90 months) vs. the other three groups with median OS ranging from 10 months for DNMT3A-mutated patients (HR 20.7, 95% CI 8.1-52.7; p<0.01) to 40 months for TET2-mutated cases with wild-type DNMT3A (HR 3.5, 95% CI 1.7-7.6; p<0.01). Results were similar for multivariable analysis of LFS, where, remarkably, none (0%) of the 25 PHF6-mutated patients with wild-type DNMT3A experienced leukemic transformation vs. 15-30% risk of leukemic transformation in the other three groups (p<0.01). Multivariable analysis for both OS and LFS, which included other risk factors such as red cell transfusion need, leukocytosis (leukocyte count ≥13 x 109/L) and karyotype, confirmed the independent and favorable impact of PHF6 mutation/wild-type DNMT3A (p<0.01 in both instances). Finally, all-inclusive multivariable analysis of karyotype and mutations, in DNMT3A wild-type patients, confirmed the highly favorable and independent prognostic impact of PHF6 mutation (HR 0.18, 95% CI 0.09-0.37).

Conclusion:

The current study proposes a 2-gene genomic signature (PHF6 mutated and DNMT3A wild-type) to identify a unique subset of CMML patients who often present with thrombocytopenia and whose clinical course is characterized by a very low risk of leukemic transformation, resulting in superior overall survival. Additional studies are warranted to validate these findings and include the information in contemporary risk models.

Disclosures: Mangaonkar: BMS: Research Funding; Incyte: Research Funding; Novartis: Research Funding. Gangat: DISC Medicine: Consultancy, Other: Advisory Board ; Agios: Other: Advisory Board. Patnaik: Polaris: Research Funding; Epigenetix: Research Funding; StemLine: Research Funding; Kura Oncology: Research Funding; Solu therapeutics: Research Funding; Astra Zeneca: Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH